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The role of resident renal mononuclear phagocytes in acute
kidney injury is controversial with experimental data
suggesting both deleterious and protective functions. To
help resolve this, we used mice transgenic for the human
diphtheria toxin receptor under the control of the CD11b
promoter and treated them with diphtheria toxin, or
liposomal clodronate, or both to deplete monocyte/
mononuclear phagocytes prior to renal ischemia/reperfusion
injury. Although either system effectively depleted circulating
monocytes and resident mononuclear phagocytes, depletion
was most marked in diphtheria toxin–treated mice. Despite
this, diphtheria toxin treatment did not protect from renal
ischemia. In contrast, mice treated with clodronate exhibited
reduced renal failure and acute tubular necrosis, suggesting
key differences between these depletion strategies.
Clodronate did not deplete CD206-positive renal
macrophages and, unlike diphtheria toxin, left resident
CD11c-positive cells unscathed while inducing dramatic
apoptosis in hepatic and splenic mononuclear phagocyte
populations. Abolition of the protected phenotype by
administration of diphtheria toxin to clodronate-treated mice
suggested that the protective effect of clodronate resulted
from the presence of a cytoprotective intrarenal population
of mononuclear phagocytes sensitive to diphtheria
toxin–mediated ablation.
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INTEGRATED INTRODUCTION, RESULTS, AND DISCUSSION
Macrophages (Mf) are recognized as key cells in both the
initiation and resolution of renal injury.1 Studies using the
administration of clodronate liposomes to induce renal Mf
apoptosis before ischemia/reperfusion injury (IRI) have
demonstrated a protected phenotype, supporting the hypoth-
esis that Mf are deleterious in the initiation/propagation
phase of renal IRI.2,3 This contrasts with data from recovery-
phase IRI, where Mf appear essential for appropriate
resolution and repair of tissue integrity2,3—analogous to
findings in other solid organs such as the liver.4
Mice transgenic for the human diphtheria toxin receptor
(DTR) under the control of the CD11b promoter (CD11b-
DTR mice) offer a potent alternative method of conditional
renal Mf ablation in vivo via administration of nanomolar
doses of diphtheria toxin (DT).5 This approach has been used
to probe the contribution of Mf to models of glomerular
and interstitial injury.6,7 This study sought to characterize the
phenotype of the Mf-ablated CD11b-DTR mouse after IRI,
and establish whether the protective effects of liposomal
clodronate-induced Mf ablation translated to protection by
alternative depletion strategies.
Animals received DT, clodronate, or saline injection 24 h
before IRI surgery to assess the functional outcome of Mf
depletion. DT-mediated Mf/monocyte depletion had no
effect on renal function 24 h after IRI, whereas clodronate
treatment induced marked functional protection (Figure 1a).
Similarly, clodronate treatment resulted in significantly
reduced acute tubular necrosis. In contrast, DT treatment
did not ameliorate the acute tubular necrosis score (Figure
1b, examples Figure 1c–f).
Mice then received either clodronate, DT, or both 24 h
before performing IRI surgery. The coadministration of DT
and clodronate demonstrated that the effect of DT was
dominant over clodronate and resulted in the loss of the
previous protected phenotype (Figure 2a). Consistent with
these functional data, the acute tubular necrosis scores were
also significantly worse in animals coadministered DT and
clodronate compared with treatment with clodronate alone
(Figure 2b, examples Figure 2c and d).
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The effects of clodronate and DT administration on
CD11b-DTR animals were compared in order to assess which
method achieved the most potent depletion of renal Mf and
circulating monocytes. Both DT and clodronate induced
significant depletion of renal Mf numbers compared with
control kidneys, with DT being most potent (Figure 3a–e).
Similarly, although both DT and clodronate induced
significant depletion of circulating monocyte numbers
compared with controls, DT was significantly more effective
(Figure 3f).
Although DT administration achieved significantly more
potent ablation of renal Mf and circulating monocytes,
markedly differing effects were seen in extrarenal organs.
Clodronate administration results in near total depletion of
the resident Mf of the spleen and liver, whereas DT
administration had no discernable effect on these resident
Mf populations (Supplemental Figure S1 online). Given the
extensive extrarenal depletion seen in clodronate adminis-
tration, circulating cytokines were assayed before and after
clodronate-based depletion. This demonstrated that clodro-
nate-based depletion resulted in increased circulating MCP-
1/CCL2 levels (P¼ 0.0006 vs. phosphate-buffered saline
(PBS)) at 24 h post depletion, but no alterations were
seen in systemic tumor necrosis factor-a, interleukin (IL)-6,
IL-10, IL-12, or interferon-g levels (Supplemental Figure S2
online). Fluorescence-activated cell sorting analysis of
enzymatically dissociated renal tissue demonstrated that
clodronate has minimal impact on resident CD11þ DC
populations within the kidney, whereas DT treatment
resulted in a significant reduction in renal CD11cþ cell
populations (Figure 4a–e). The proportion of renal Mf
expressing the M2 phenotypic marker CD206 (mannose
receptor) increased from 10.4±2.2 to 18.7±2.4% in the
aftermath of clodronate administration (P¼ 0.02 vs. PBS;
Figure 4f and g). Further analysis of the CD206þ cells as a
proportion of total renal cells indicated that this change in
proportion reflected their count remaining stable pre/post
depletion, with M1/M0 Mf being killed (data not shown).
Time-course studies indicated that administration of DT
to CD11b-DTR animals resulted in a 490% ablation of
circulating monocytes at 24 h, with total counts remaining
significantly lower than control animals at 48 h. Analysis
of the key monocyte subsets (Gr1þCCR2þCX3CR1 and
Gr1CCR2CX3CR1þ ) demonstrated that both subsets are
equally depleted at 24 h, with full recovery of Gr1þ mono-
cytes but not of Gr1 monocytes at 48 h (Figure 4h). DT
administration does not cause any depletion of neutrophils
at 24 h (Figure 4j).
Clodronate reduced circulating total monocyte count by
76% after 24 h (Figure 4i), with recovery evident at 48 h. Both
Gr1þ and Gr1 subsets were equally depleted at 24 h.
Inflammatory Gr1þ monocytes rebounded to higher than
control levels at 48 h (Figure 4i). Prolonged depletion of
Gr1 monocytes was observed. Neutrophils were unaffected
by clodronate (Figure 4j).
This work demonstrates contrasting effects of two
differing strategies of Mf depletion on the functional and
structural outcome after renal IRI. DT administration on
CD11b-DTR mice has previously proven to be protective in
various models of acute renal inflammation,6,7 and we
expected to find a similar protective phenotype in renal IRI.
However, despite inducing significantly more marked abla-
tion of renal Mf and circulating monocytes, DT-mediated
depletion had no protective effect on renal function or acute
tubular necrosis. In contrast, clodronate administration
induced significant renoprotection in accordance with
previous studies.2,3
The coadministration of DT and clodronate completely
abolished the protected phenotype evident following the
administration of clodronate alone, and this is an important
result as investigators typically use one Mf/monocyte
ablation methodology. DT administration per se is unlikely
to be nephrotoxic in the light of previous studies using the
administration of multiple doses of DT.6,8
Although much previous work has suggested that both
circulating monocytes9 and renal Mf6,8 are injurious in renal
IRI, the complete lack of renal protection in CD11b-DTR
mice administered both DT and clodronate suggests that the
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Figure 1 |Differing effects of monocyte/macrophage ablation
induced by clodronate or diphtheria toxin (DT). The
administration of clodronate 24 h before the induction of renal
ischemia/reperfusion injury (IRI) results in improved kidney
function 24 h following injury, whereas DT treatment has no
protective effect (a, n¼ 9–10 per group). A similar pattern was
seen on histological assessment of the extent of acute tubular
necrosis with clodronate, resulting in reduced structural injury (b).
Representative examples of normal kidney tissue (c), control IRI
(d), IRIþ clodronate treatment (e), and IRIþDT treatment (f) (all
images at  50 magnification).
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situation may be more complicated. The abolition of
clodronate-induced protection by DT suggests the existence
of a renoprotective population of Mf that are maintained in
the aftermath of clodronate treatment but which are sensitive
to DT-induced ablation. As a result, these findings challenge
the recent tenet that Mf are intrinsically pathogenic in the
initiation of renal IRI,2,3 instead suggesting encompassing
roles for Mf populations in both propagating tissue injury
and promoting parenchymal cell survival and function.
Indeed, our recent studies suggest that upregulation of the
anti-inflammatory enzyme heme-oxygenase-1 by renal Mf is
an early cytoprotective response in IRI.10
The data presented in this study illustrate an important
technical consideration in that the mode by which cell
depletion is achieved may confound the interpretation of the
effects attributed to the cell population of interest. For
example, it still remains conceivable, given the immuno-
modulatory properties of apoptotic cells11 that the beneficial
impact of clodronate may, at least in part, result from the
significant apoptosis induced in liver and spleen—key
immunological organs. Were such a phenomena to account
for the findings seen, the serum cytokine results would
indicate that the mechanism is independent of a systemic
alteration in levels of candidate factors such as tumor
necrosis factor-a, IL-10, or IL-6. In our experiments, this
possibility would require any protective effect of the
clodronate-induced extrarenal cell death to act via DT
sensitive cells.
All currently available strategies of ‘selective’ renal mono-
nuclear phagocyte depletion (clodronate, CD11b-DTR, or
CD11c-DTR mice) will exhibit simultaneous, albeit variable,
effects on both Mf and DC populations if these terms are
used to describe F4/80þ (Mf) and CD11cþ (DC) cells. Such
difficulties in discrimination and nomenclature arise from
the widespread co-expression of the mononuclear phagocyte
markers CD11b, F4/80, and CD11c within the kidney, leading
to a growing move to consider the resident mononuclear
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Figure 2 |Administration of diphtheria toxin (DT) abolishes
the protective effect of clodronate treatment. Mice were
treated with either clodronate, DT, or both 24 h before the
induction of renal ischemia/reperfusion injury (IRI). Clodronate
again protected renal function, but this effect was abolished by
the coadministration of DT (a, n¼ 6 per group). Similarly, the
addition of DT to clodronate-treated animals resulted in a loss of
the structural protection exhibited in clodronate-alone treatment
(b). Representative examples of histological injury in
IRIþ clodronate administration (c) and IRIþ clodronate/DT
coadministration (d) (all images at  50 magnification).
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Figure 3 |Diphtheria toxin (DT) depletes circulating monocytes and renal macrophages (M/) more potently than clodronate.
Immunohistochemistry for the Mf marker F4/80 demonstrates that both DT and clodronate deplete resident renal Mf compared with
control kidneys (a, uninjured control kidney; b, post- ischemia/reperfusion injury (IRI) control kidney; c, IRIþ clodronate; d, IRIþDT, all
images  200). Quantification of renal Mf numbers 24 h post administration indicates that DT treatment induces the most marked ablation
of F4/80þ Mf (e, *P¼ 0.007 DT vs. clodronate, **P¼ 0.0022 clodronate vs. control, ***P¼ 0.0002 DT vs. control). Flow cytometric analysis of
whole blood all counts per high powered field (hpf) indicated that DT treatment induces the most marked ablation of circulating monocytes
(f, *Po0.05 DT vs. clodronate, **P¼ 0.0003 clodronate, **Po0.0002 DT vs. control).
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phagocyte compartment as a single but functionally diverse
cell population.12
As both DT and clodronate induced significant depletion of
circulating monocytes that have been shown to be pathogenic
in renal IRI,9 it seems more likely that the different renal
outcomes of DT and clodronate may relate to the number and
phenotype of the residual intrarenal Mf. Our data would
support the presence of a cytoprotective renal Mf population
following clodronate treatment. Unlike DT, clodronate-induced
killing is phagocytosis dependent. Thus, Mf populations that
survive clodronate treatment might either exhibit less avid
phagocytic behavior or reside in microenvironments not
penetrated by the administered liposomes.
We noted a preserved CD11cþ cell population after
clodronate treatment but not after DT treatment, implicating
a Mf/DC population in mediating protection after IRI. This
is consistent with work in both cisplatin-induced acute
kidney injury and nephrotoxic nephritis, as the use of the
CD11c-DTR animal to deplete CD11cþ cells resulted in
augmented tissue injury,13,14 although this model also
depletes F4/80þ cells within the kidney.15 However, early
reports in the CD11c-DTR strain suggest that depletion here
results in a protected phenotype after IRI,16 arguing against a
CD11cþ population being key to renal protection after
clodronate treatment. CD11cþ renal cells have been demon-
strated to mediate subsequent recruitment of inflammatory
leukocytes via early release of tumor necrosis factor-a, and
thus implicated in the propagation of renal injury.17 Recent
work has demonstrated that the ‘propagation phase’ of IRI
is characterized by the presence of M1 renal Mf, with the
successful resolution of injury requiring a switch to an M2
activation state.18 Our finding of increased relative propor-
FL4-H: CD11c APC
100 101 102 103 104
FL4-H: CD11c APC
100 101 102 103 104
FL4-H: CD11c APC
100 101 102 103 104
FL4-H: CD11c APC
100 101 102 103 104
100
101
102 0.2 2.24 1.53 0.61
103
104
SS
C-
H
100
101
102
103
104
SS
C-
H
100
101
102
103
104
SS
C-
H
100
101
102
103
104
SS
C-
H
2.25
a
e
h i j
f g
b c d
2.00
1.75
1.50
1.25
1.00
CD
11
c+
 a
s 
%
 o
f t
ot
al
 c
el
ls
0.75
0.50
0.25
0.00
Control Clodronate DT
P =0.0303
Anti-mannose receptor - PE
%
 O
f m
ax
Clodronate
PBS
Isotype Ab
100
80
60
40
20
0
0 102 103 104 105
%
 M
ac
ro
ph
ag
es
 C
D2
06
hi
25
20
15
10
5
0
Post PBS Post clod
P=0.02
M
on
oc
yt
es
/m
l
Controls GR1hi9.0×105
8.0×105
7.0×105
6.0×105
5.0×105
4.0×105
3.0×105
2.0×105
1.0×105
0
Pre 24-h post 48-h post
***
***
**
Controls GR1lo
DT 25 ng/g gr1hi
DT 25 ng/g gr1lo
M
on
oc
yt
es
/m
l
Controls GR1hi
Controls GR1lo
Clodronate GR1hi
Clodronate GR1lo
1.8×106
1.5×106
1.2×106
1.0×106
7.5×105
5.0×105
2.5×105
0
Pre 24-h post 48-h post 72-h post
***
***
**
*PM
N
 p
er
 m
l/b
lo
od
Control
DT
Clodronate
9.0×106
8.0×106
7.0×106
6.0×106
5.0×106
4.0×106
3.0×106
2.0×106
1.0×106
0
24-h post Rx 48-h post Rx
24-h post IRI
Figure 4 | Effect of diphtheria toxin (DT) and clodronate on renal and circulating leukocytes. Flow cytometric analysis of enzymatically
dissociated renal tissue demonstrates that CD11cþ cells are significantly depleted by DT treatment but not by clodronate administration
(a, isotype control; b, staining with CD11c-APC demonstrates CD11cþ renal cells (highlighted); c, pretreatment with intravenous
clodronate; d, DT pretreatment; e, summary of quantification). Further digests revealed a relative increase in the proportions of mannose
receptor (CD206)–expressing macrophages (Mf) in the kidney compared with control animals (f, representative CD206 histogram; g, graph
of proportion of Mf CD206hi P¼ 0.02 vs. phosphate-buffered saline (PBS), n¼ 4 per group). Both DT (h) and clodronate (i) result in marked
depletion of both Gr1hi and Gr1low monocyte subsets at 24 h after administration, with complete reconstitution of Gr1hi monocytes at 48 h
post administration. Neither method of monocyte/Mf ablation reduces polymorphonuclear neutrophil (PMN) counts (j). *Po0.05,
**Po0.01, ***Po0.001 for comparisons between groups at each time point.
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tions of resident M2 Mf may therefore be of importance in
mediating post-injury outcome. Further work will be
required to further dissect these issues.
Overall consideration of this study and data from renal
IRI10 and studies of cisplatin-induced acute kidney injury in
CD11c-DTR mice14,19 raises a further important question:
are the cytoprotective properties of resident Mf inherent as
suggested by recent work20,21 or might this phenotype be
‘induced’ by the experimental manipulation used? Many
experimental systems used to probe Mf/DC function induce
Mf or DC apoptosis, and apoptotic cells may modulate the
phenotype of the remaining Mf/DCs. For example, apoptotic
cells may inhibit DC maturation22 and induce an anti-inflam-
matory phenotype with increased local IL-10 production.23,24
Our data demonstrate that profound monocyte/Mf
depletion is not protective per se, and instead supports a
model in which the remaining subset of renal Mf are capable
of improving outcome after IRI if present in sufficient
numbers in the initial 24 h after injury. The marked
differences in function outcome between different methodol-
ogies of monocyte/Mf depletion indicates that care must be
taken in both the design and interpretation of studies
assessing the purported pathogenic significance of mono-
nuclear phagocyte populations via in vivo depletion.
SUPPLEMENTAL CONCISE METHODS
Murine model of IRI
Six- to eight-week-old male mice on the FVB/n strain background
were used from in-house colonies. Procedures were performed
under Home Office licenses as previously described.10 During the
20-min ischemic period, body temperature was maintained using a
heating blanket with homeostatic control (Harvard Apparatus,
Boston, MA) via a rectal temperature probe. Blood and tissue
samples were obtained at the time of surgery (d0) and 24 h post-
surgery (d1) under terminal anesthesia.
Induction of monocyte/M/ depletion
Clodronate liposomes were purchased from Professor Nico van
Rooijen of Vrije University, The Netherlands (www.clodronatelipo-
somes.org). These were prepared as previously described.25 After
warming and resuspension of the liposomes, a dose of 200ml was
administered intravenously to induce macrophage depletion.
CD11b-DTR animals on the FVB/N background expressing the
receptor for the human DTR under the control of the CD11b
promoter were used as previously described.6 On the basis of
previous work, a dose of 25 ng/g body weight of DT or matched
volume of PBS was administered to CD11b-DTR animals 24 h
before IRI, to induce renal and circulating monocyte ablation.
Surgery was performed 24 h after depletion.
Collection and staining of whole blood for leukocyte
populations
To quantify circulating leukocytes, 25 ml of whole blood was
venesected via a tail vein nick into an equal volume of 4.5% citrate
solution, resulting in immediate anticoagulation of the collected
blood before storage on ice. A volume of 2 25ml of the blood
samples was pipetted into fluorescence-activated cell sorting tubes
and stained for 30 min on ice with 0.5 ml CD11b-FITC, 0.5 ml Gr1-
PE, 0.5 ml F4/80-APC, 5 ml mouse serum, and 43.5 ml PBS without
Ca2þ /Mg2þ . Conjugated antibodies were purchased from BD
Biosciences (Oxford, UK), eBiosciences (Hatfield, UK), and Caltag
(Little Balmer, UK).
Red blood cell lysis was performed using BD FACSLyse solution
(BD Biosciences) before sample acquisition on a BD FACSCaliber
cytometer. Immediately before acquisition, 50 ml of BD Flowcheck
bead suspension (equating toB50,000 FL3 bright beads) was added
to each sample tube, followed by brief agitation. Sample acquisition
was terminated after 5000 bead events had been counted, equating
to 1/10th of the total experimental volume. By using the FlowJo
software (Treestar, Ashland, OR), whole-blood leukocyte popula-
tions were collected and mononuclear and polymorphonuclear
populations differentiated based on forward and side scattering
characteristics. Further criteria were applied before a cell was
definitively identified as belonging to a distinct lineage. In each case,
the cell was provisionally identified on the basis of appropriate
forward and side scattering characteristics. Surface markers were
then examined—neutrophil cells were also CD11bmid/hi and Gr1hi,
whereas monocytes were CD11bhi and Gr1hi or low, as the Gr1
antibody clone identifies both the Ly6c and Ly6g antigens.
Assessment of renal function
Plasma samples were prepared from whole blood and analyzed by
the Jaffe method (Alpha Laboratories, Eastleigh, UK) on a Cobas
Fara Centrifugal Analyser (Roche Diagnostics, Burgess Hill, UK)
according to the manufacturer’s instructions.
Immunohistochemistry
Whole kidneys were cut longitudinally and fixed in methyl Carnoy’s
solution (60% methanol, 30% chloroform, and 10% acetic acid)
before embedding in paraffin. Tissue sections (4 mm) were cut and
stained with hematoxylin and eosin for assessment of medullary
tubular necrosis. Renal Mf were identified by immunostaining for
the tissue Mf marker F4/80. Embedded tissue was deparaffinized in
xylene, rehydrated, and blocked using 3% H202 before incubation
with monoclonal rat anti-F4/80 (1/250 dilution; Caltag Labora-
tories, Northampton, UK). Rat anti-mouse antibodies were
incubated at 4 1C overnight with subsequent incubation with
mouse-adsorbed biotinylated rabbit anti-rat immunoglobulin G
(1/300 dilution; Vector Laboratories, Peterborough, UK) at room
temperature for 30 min. After washing, sections were incubated with
Vectastain ABC Elite reagent (Vector Laboratories) for 30 min at
room temperature, before washing and staining with diaminoben-
zidine (Dako UK, Cambridgeshire, UK). Hematoxylin counter-
staining was performed before mounting. In all cases, appropriate
isotype antibodies were used as negative controls. Mf counts were
expressed as mean cells per  400 microscope field, with five fields
being assessed per area. Tubules within the outer stripe of the outer
medulla (OSOM) were photographed and were counted as viable or
necrotic based on nuclear morphology and integrity of the epithelial
cell layer using the ImageJ software (Cell_counter plugin; ImageJ
1.36b; National Institutes of Health, Bethesda, MD).
Kidney digestion for flow cytometric analysis
For fluorescence-activated cell sorting analysis, kidneys were
fragmented using a scalpel into ice-cold RPMI 1640. They were
then resuspended in 2 ml RPMI containing 1.6 mg/ml collagenase B
and 100 mg/ml DNAse I (both from Roche Applied Science,
Penzberg, Germany), and incubated at 37 1C for 45 min. Cells were
pelleted and resuspended in 1 ml of RPMI with 100 mg/ml of DNAse
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I alone for a further 15 min at room temperature. Cell samples were
centrifuged, resuspended, and passed through a 40-mm cell strainer
before flow cytometry. Red blood cells were lysed by incubation on
ice with ammonium chloride lysis buffer for 10 min. Cells were pelleted
and resuspended in 1 ml Dulbecco’s PBS (without Ca2þ /Mg2þ ) for
counting on a hemocytometer, and 5 105 cells were blocked on ice
for 20 min with 10% mouse serum, and then stained with anti-
CD206-PE (clone MR5D3, AbD Serotec, Kidlington, UK) and pre-
viously described antibodies for 30 min before data acquisition.
Serum cytokine analysis
Measurement of inflammatory cytokines was undertaken on serum
samples taken before injection of clodronate, 24 h post injection
(pre-IRI) and 24 h post IRI. Analysis was undertaken using the
BD Mouse Inflammation CBA kit to measure IL-6, IL-10, MCP-
1, interferon-g, tumor necrosis factor-a, and IL-12p70 on 50 ml
of serum as per the manufacturer’s instructions. Sample
acquisition was performed on a BD FACSArray instrument
(BD, Oxford, UK).
Statistical analysis
All data are expressed as mean±s.e.m. The Student’s unpaired t-test
was used to compare two groups. Instances in which multiple
conditions were compared, a one-way analysis of variance for repeated
measurements was used. P-values o0.05 were considered statistically
significant. All statistical analyses were performed using GraphPad
Prism version 4.0c for Macintosh (GraphPad Software, San Diego, CA).
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SUPPLEMENTARY MATERIAL
Figure S1. Clodronate but not DT administration results in profound
loss of resident F4/80þ Mf from both spleen and liver (Spleen
images  50, Liver  200).
Figure S2. Serial sampling of serum cytokines from mice prior to
injection with i.v. Clodronate liposomes or control PBS (Baseline), 24 h
after injection but prior to IRI surgery (pre IRI) and 24 h following IRI
surgery demonstrate that clodronate administration results in a
marked increase in MCP-1 (***P¼ 0.0006 vs PBS), but no
augmentation of IL-10 or TNF-alpha prior to IRI.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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